Pharmacogenetic Testing: A Tool for Personalized Drug Therapy Optimization

• Published in: Pharmaceutics Vol. 12; no. 12; p. 1240
• Main Authors: Malsagova, Kristina A, Butkova, Tatyana V, Kopylov, Arthur T, Izotov, Alexander A, Potoldykova, Natalia V, Enikeev, Dmitry V, Grigoryan, Vagarshak, Tarasov, Alexander, Stepanov, Alexander A, Kaysheva, Anna L
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 19-12-2020; MDPI
• Subjects: Biomarkers; Clinical medicine; Drug dosages; Drug therapy; Enzymes; Gene expression; genetic polymorphism; Genomes; Genotype & phenotype; Laboratories; Medical research; Metabolism; Mutation; Patients; personalized medicine; Pharmacodynamics; pharmacogenetic test; pharmacogenetics; Pharmacokinetics; Precision medicine; Review; pharmacogenetic test; genetic polymorphism; pharmacogenetics; personalized medicine
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics12121240

Pharmacogenomics is a study of how the genome background is associated with drug resistance and how therapy strategy can be modified for a certain person to achieve benefit. The pharmacogenomics (PGx) testing becomes of great opportunity for physicians to make the proper decision regarding each non-trivial patient that does not respond to therapy. Although pharmacogenomics has become of growing interest to the healthcare market during the past five to ten years the exact mechanisms linking the genetic polymorphisms and observable responses to drug therapy are not always clear. Therefore, the success of PGx testing depends on the physician's ability to understand the obtained results in a standardized way for each particular patient. The review aims to lead the reader through the general conception of PGx and related issues of PGx testing efficiency, personal data security, and health safety at a current clinical level.